2. Brożek JL, Bousquet J, Agachee I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017; 140 (6).
3. Janson C, Johannessen A, Franklin K et al. Change in the prevalence asthma, rhinitis and respiratory symptom over a 20 year period: associations to year of birth, life style and sleep related symptoms 2018. DOI: 10.1186/s12890-018-0690-9
4. Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am 2016; 36 (2): 235–48.
5. Meltzer EO, Blaiss MS, Naclerio RM et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 2012; 33 (5): 113–41.
6. Roxbury CR, Qiu M, Shargorodsky J. Association between allergic rhinitis and poor sleep parameters in US adults. Int Forum Allergy Rhinol 2018; 8 (10): 1098–106.
7. Robinson S, Buchs S, Hammerby E et al. A Review of The Quality of Life and Educational Burden of Allergic Rhinitis on Adolescents. Value Health 2017; 20 (9): 648.
8. Павлова К.С. Аллергический ринит. Мед. совет. 2013; 1: 89–96. / Pavlova K.S. Allergicheskii rinit. Med. sovet. 2013; 1: 89–96. [in Russian]
9. Vlastos I, Athanasopoulos I, Mastronikolis NS et al. Impaired mucociliary clearance in allergic rhinitis patients is related to a predisposition to rhinosinusitis. Ear Nose Throat J 2009; 88 (4): 17–9.
10. Kreiner-Moller E, Chawes BL, Caye-Thomasen P et al. Allergic rhinitis is associated with otitis media with effusion: a birth cohort study. Clin Exp Allergy 2012; 42 (11): 1615–20.
11. Luong A, Roland PS. The link between allergic rhinitis and chronic otitis media with effusion in atopic patients. Otolaryngol Clin North Am 2008; 41 (2): 311–23.
12. Морозова С.В., Карапетян Л.С. Актуальная гипосенсибилизирующая терапия аллергического ринита. Мед. совет. 2018; 8: 76–9. / Morozova S.V., Karapetian L.S. Aktual'naia giposensibiliziruiushchaia terapiia allergicheskogo rinita. Med. sovet. 2018; 8: 76–9. [in Russian]
13. Platts-Mills TA, Vervloet D, Thomas WR et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997; 100 (6): 2–24.
14. Piacentini GL, Martinati L, Mingoni S, Boner AL. Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. J Allergy Clin Immunol 1996; 97 (5): 1079–84.
15. Sharma HP, Hansel NN, Matsui E et al. Indoor environmental influences on children's asthma. Pediatr Clin North Am 2007; 54 (1): 103–20.
16. Platts-Mills TA. Allergen avoidance in the treatment of asthma and allergic rhinitis. UpToDate Updated October 2016.
17. Maloney J, Bernstein DI, Nelson H et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112: 146–53.
18. Creticos PS, Maloney J, Bernstein DI et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013; 131: 1342–9.
19. Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med 2015; 372 (5): 456–63.
20. Wallace DV, Dykewicz MS, Bernstein DI et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122: 1–84.
21. Small P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol 2011; 7 (1): 3.
22. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 896: 479–84.
23. Wallace DV, Dykewicz MS, Bernstein DI et al. J Allergy Clin Immunol 2008; 122 (2): 1–84.
24. Pullerits T, Praks L, Ristioja V et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949–55.
25. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624–9.
26. Biggadike K. Fluticasone furoate/fluticasone propionate – different drugs with different properties. Clin Respiratory J 2011; 5 (3): 183–4.
27. Ильина Н.И., Козлов В.С., Павлова К.С. и др. Опыт применения флутиказона пропионата у пациентов с аллергическим ринитом в России. Болезни органов дыхания (Прил. к журн. Consilium Medicum). 2008; 1: 58–61. / Il'ina N.I., Kozlov V.S., Pavlova K.S. i dr. Opyt primeneniia flutikazona propionata u patsientov s allergicheskim rinitom v Rossii. Respiratory Organs Diseases (Suppl. Consilium Medicum). 2008; 1: 58–61. [in Russian]
28. Carr WW, Ratner P, Munzel U et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc 2012; 33 (6): 45–9.
29. Small P, Frenkiel S, Becker A et al. The Canadian Rhinitis Working Group: Rhinitis: A practical and comprehensive approach to assessment and therapy. J Otolaryngol 2007; 36 (1): 5–27.
30. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012; 22: 1–12.
31. Allen DB, Meltzer EO, Lemanske RFJr et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23: 407–13.
32. Groupa FP. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994; 125: 628–34.
33. Bernstein DI, Levy AL, Hampel FC et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004; 34: 952–7.
34. Ratner P, Van Bavel J, Mohar D et al. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2015; 114 (2): 141–7.
35. Hadley JA, Derebery JM, Marple BF. Comorbidities and allergic rhinitis: not just a runny nose. J Fam Pract 2012; 61 (2): 11–5.

________________________________________________

1. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125: 103–15.
2. Brożek JL, Bousquet J, Agachee I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017; 140 (6).
3. Janson C, Johannessen A, Franklin K et al. Change in the prevalence asthma, rhinitis and respiratory symptom over a 20 year period: associations to year of birth, life style and sleep related symptoms 2018. DOI: 10.1186/s12890-018-0690-9
4. Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am 2016; 36 (2): 235–48.
5. Meltzer EO, Blaiss MS, Naclerio RM et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 2012; 33 (5): 113–41.
6. Roxbury CR, Qiu M, Shargorodsky J. Association between allergic rhinitis and poor sleep parameters in US adults. Int Forum Allergy Rhinol 2018; 8 (10): 1098–106.
7. Robinson S, Buchs S, Hammerby E et al. A Review of The Quality of Life and Educational Burden of Allergic Rhinitis on Adolescents. Value Health 2017; 20 (9): 648.
8. Pavlova K.S. Allergicheskii rinit. Med. sovet. 2013; 1: 89–96. [in Russian]
9. Vlastos I, Athanasopoulos I, Mastronikolis NS et al. Impaired mucociliary clearance in allergic rhinitis patients is related to a predisposition to rhinosinusitis. Ear Nose Throat J 2009; 88 (4): 17–9.
10. Kreiner-Moller E, Chawes BL, Caye-Thomasen P et al. Allergic rhinitis is associated with otitis media with effusion: a birth cohort study. Clin Exp Allergy 2012; 42 (11): 1615–20.
11. Luong A, Roland PS. The link between allergic rhinitis and chronic otitis media with effusion in atopic patients. Otolaryngol Clin North Am 2008; 41 (2): 311–23.
12. Morozova S.V., Karapetian L.S. Aktual'naia giposensibiliziruiushchaia terapiia allergicheskogo rinita. Med. sovet. 2018; 8: 76–9. [in Russian]
13. Platts-Mills TA, Vervloet D, Thomas WR et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997; 100 (6): 2–24.
14. Piacentini GL, Martinati L, Mingoni S, Boner AL. Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. J Allergy Clin Immunol 1996; 97 (5): 1079–84.
15. Sharma HP, Hansel NN, Matsui E et al. Indoor environmental influences on children's asthma. Pediatr Clin North Am 2007; 54 (1): 103–20.
16. Platts-Mills TA. Allergen avoidance in the treatment of asthma and allergic rhinitis. UpToDate Updated October 2016.
17. Maloney J, Bernstein DI, Nelson H et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112: 146–53.
18. Creticos PS, Maloney J, Bernstein DI et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013; 131: 1342–9.
19. Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med 2015; 372 (5): 456–63.
20. Wallace DV, Dykewicz MS, Bernstein DI et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122: 1–84.
21. Small P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol 2011; 7 (1): 3.
22. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 896: 479–84.
23. Wallace DV, Dykewicz MS, Bernstein DI et al. J Allergy Clin Immunol 2008; 122 (2): 1–84.
24. Pullerits T, Praks L, Ristioja V et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949–55.
25. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624–9.
26. Biggadike K. Fluticasone furoate/fluticasone propionate – different drugs with different properties. Clin Respiratory J 2011; 5 (3): 183–4.
27. Il'ina N.I., Kozlov V.S., Pavlova K.S. i dr. Opyt primeneniia flutikazona propionata u patsientov s allergicheskim rinitom v Rossii. Respiratory Organs Diseases (Suppl. Consilium Medicum). 2008; 1: 58–61. [in Russian]
28. Carr WW, Ratner P, Munzel U et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc 2012; 33 (6): 45–9.
29. Small P, Frenkiel S, Becker A et al. The Canadian Rhinitis Working Group: Rhinitis: A practical and comprehensive approach to assessment and therapy. J Otolaryngol 2007; 36 (1): 5–27.
30. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012; 22: 1–12.
31. Allen DB, Meltzer EO, Lemanske RFJr et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23: 407–13.
32. Groupa FP. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994; 125: 628–34.
33. Bernstein DI, Levy AL, Hampel FC et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004; 34: 952–7.
34. Ratner P, Van Bavel J, Mohar D et al. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2015; 114 (2): 141–7.
35. Hadley JA, Derebery JM, Marple BF. Comorbidities and allergic rhinitis: not just a runny nose. J Fam Pract 2012; 61 (2): 11–5.

В.М.Свистушкин*, П.А.Кочетков, Е.С.Щенникова, О.Ю.Карпова

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

________________________________________________

V.M.Svistushkin*, P.A.Kochetkov, E.S.Shchennikova, O.Yu.Karpova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*svvm3@yandex.ru